ams banner image

Clinical decision support, powered by Rippledown

Decision Support for Enhanced Clinical Management
ams banner image
ams banner image
ams banner image

Support your teams with RippleDown

  • Assist doctors analyzing huge quantities of data 
  • Help promote care within institution protocols and established guidelines
  • Automate the burdensome process of customizing the EMR for specific clinical needs

77% of physicians would value interpretation assistance1

 

The Value of Rippledown 

Case-based rules engine delivers patient-specific content.

Intelligent insights are unlocked – directly related to patient care decisions.

Physicians receive supportive guidance and protocol reinforcement

LEVERAGE THE POWER OF LAB DATA AND YOUR EXISTING WORKFLOWS TO DIRECTLY IMPACT CLINICAL DECISION-MAKING WITH RIPPLEDOWN

Provide customized, patient-specific information

RippleDown enables physicians to improve result interpretation and take targeted actions.

Patient-specific outputs

Reduced variability

Easy updates as guidelines change

Existing workflows

 

Contact Us

Find out how AlinIQ Clinical Decision Support, Powered by RippleDown and the family of AlinIQ Digital Health Solutions can help your organization elevate testing and empower your clinicians with patient-specific insights that support targeted action.

Realize your potential

Aliniq digital health solutions

AlinIQ, the suite of Digital Health Solutions from Abbott, helps you uncover intelligent insights from your laboratory data and discover greater operational productivity with existing resources.

Imagen del banner web de AlinIQ
Imagen del banner web de AlinIQ

EXPLORE

Knowledge Center

Find the latest information in laboratory science, therapeutic areas and Abbott innovation.

Customer Portal

Receive exclusive benefits and resources when you register to access to the  customer portal.

Contact Us

Abbott's Representatives are ready to offer support, gather feedback, and answer any questions.

References
  1. “Urgency for the Clinical Laboratory.” Economist Intelligence Unit. 3/2021